Analysts See $-0.39 EPS for Aldeyra Therapeutics, Inc. (ALDX)

July 14, 2018 - By James Guidry

Investors sentiment increased to 3 in 2018 Q1. Its up 1.38, from 1.62 in 2017Q4. It is positive, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 6 reduced holdings. 10 funds opened positions while 17 raised stakes. 10.28 million shares or 3.03% more from 9.98 million shares in 2017Q4 were reported.
Fmr Ltd Com accumulated 1.61 million shares. Jefferies Ltd Limited Liability Company, New York-based fund reported 11,900 shares. Element Capital Mngmt Lc stated it has 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Perceptive Advsr Ltd Llc holds 0.65% or 3.09M shares. Acadian Asset Mngmt Ltd Liability reported 0% stake. Peddock Capital Advisors Lc holds 0% or 752 shares in its portfolio. Weiss Multi holds 47,400 shares. Bluecrest Management holds 14,371 shares. Tower Capital Ltd Liability Company (Trc) owns 1,053 shares or 0% of their US portfolio. Geode Cap Ltd Limited Liability Company stated it has 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Private Ocean stated it has 1,000 shares or 0% of all its holdings. Drw Secs Lc reported 12,000 shares or 0.01% of all its holdings. Renaissance Technology Limited Liability holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 30,600 shares. Goldman Sachs Group holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 15,567 shares. Sphera Funds holds 1.01 million shares or 1.15% of its portfolio.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.39 EPS on August, 14.They anticipate $0.04 EPS change or 11.43 % from last quarter’s $-0.35 EPS. After having $-0.43 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see -9.30 % EPS growth. The stock increased 1.79% or $0.15 during the last trading session, reaching $8.55. About 94,454 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 82.11% since July 14, 2017 and is uptrending. It has outperformed by 69.54% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since January 26, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of ALDX in report on Tuesday, June 26 with “Buy” rating. The firm earned “Buy” rating on Tuesday, May 15 by Cantor Fitzgerald. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, March 29 report.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $171.94 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Prnewswire.com which released: “Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes” on June 25, 2018. Also Streetinsider.com published the news titled: “Aldeyra Therapeutics (ALDX) Reports Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial” on July 12, 2018. Prnewswire.com‘s news article titled: “Aldeyra Therapeutics Announces 2018 Research Day” with publication date: June 20, 2018 was also an interesting one.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: